RASAL2 promotes tumor progression through LATS2/YAP1 axis of hippo signaling pathway in colorectal cancer

被引:59
|
作者
Pan, Yi [1 ,2 ,3 ]
Tong, Joanna Hung Man [1 ,2 ,3 ]
Lung, Raymond Wai Ming [1 ,2 ,3 ]
Kang, Wei [1 ,2 ,3 ]
Kwan, Johnny Sheung Him [1 ,2 ]
Chak, Wing Po [1 ,2 ,3 ]
Tin, Ka Yee [1 ,2 ]
Chung, Lau Ying [1 ,2 ,3 ]
Wu, Feng [1 ,2 ,3 ]
Ng, Simon Siu Man [3 ,4 ]
Mak, Tony Wing Chung [4 ]
Yu, Jun [3 ,5 ]
Lo, Kwok Wai [1 ,2 ]
Chan, Anthony Wing Hung [1 ,2 ]
To, Ka Fai [1 ,2 ,3 ]
机构
[1] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, State Key Lab Oncol South China, 30-32 Ngan Shing St, Shatin, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Sir K Pao Canc Ctr, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China
[3] Chinese Univ Hong Kong, Inst Digest Dis, Partner State Key Lab Digest Dis, Hong Kong, Hong Kong, Peoples R China
[4] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Div Colorectal Surg, Hong Kong, Hong Kong, Peoples R China
[5] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China
关键词
RASAL2; Hippo; LATS2; YAP1; Colorectal cancer; YES-ASSOCIATED PROTEIN; EPITHELIAL-MESENCHYMAL TRANSITION; CELL-PROLIFERATION; METASTASIS; EXPRESSION; GENE; YAP; ASSOCIATION; SUPPRESSES; NETWORKS;
D O I
10.1186/s12943-018-0853-6
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Patients with colorectal cancer (CRC) have a high incidence of regional and distant metastases. Although metastasis is the main cause of CRC-related death, its molecular mechanisms remain largely unknown. Methods: Using array-CGH and expression microarray analyses, changes in DNA copy number and mRNA expression levels were investigated in human CRC samples. The mRNA expression level of RASAL2 was validated by qRT-PCR, and the protein expression was evaluated by western blot as well as immunohistochemistry in CRC cell lines and primary tumors. The functional role of RASAL2 in CRC was determined by MTT proliferation assay, monolayer and soft agar colony formation assays, cell cycle analysis, cell invasion and migration and in vivo study through siRNA/shRNA mediated knockdown and overexpression assays. Identification of RASAL2 involved in hippo pathway was achieved by expression microarray screening, double immunofluorescence staining and co-immunoprecipitation assays. Results: Integrated genomic analysis identified copy number gains and upregulation of RASAL2 in metastatic CRC. RASAL2 encodes a RAS-GWase-activating protein (RAS-GAP) and showed increased expression in CRC cell lines and clinical specimens. Higher RASAL2 expression was significantly correlated with lymph node involvement and distant metastasis in CRC patients. Moreover, we found that RASAL2 serves as an independent prognostic marker of overall survival in CRC patients. In vitro and in vivo functional studies revealed that RASAL2 promoted tumor progression in both KRAS/NRAS mutant and wild-type CRC cells. Knockdown of RASAL2 promoted YAP1 phosphorylation, cytoplasm retention and ubiquitination, therefore activating the hippo pathway through the LATS2/YAP1 axis. Conclusions: Our findings demonstrated the roles of RASAL2 in CRC tumorigenesis as well as metastasis, and RASAL2 exerts its oncogenic property through LATS2/YAP1 axis of hippo signaling pathway in CRC.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Inactivation of Lats1 and Lats2 highlights the role of hippo pathway effector YAP in larynx and vocal fold epithelium morphogenesis
    Mohad, Vidisha
    Lungova, Vlasta
    Verheyden, Jamie
    Thibeault, Susan L.
    DEVELOPMENTAL BIOLOGY, 2021, 473 : 33 - 49
  • [22] The Hippo/YAP1 pathway interacts with FGFR1 signaling to maintain stemness in lung cancer
    Lu, Tingting
    Li, Ziming
    Yang, Ying
    Ji, Wenxiang
    Yu, Yongfeng
    Niu, Xiaomin
    Zeng, Qingyu
    Xia, Weiliang
    Lu, Shun
    CANCER LETTERS, 2018, 423 : 36 - 46
  • [23] A FUS-LATS1/2 Axis Inhibits Hepatocellular Carcinoma Progression via Activating Hippo Pathway
    Bao, Le
    Yuan, Lei
    Li, Pengfei
    Bu, Qingyun
    Guo, Aijun
    Zhang, Hui
    Cui, Ning
    Liu, Bin
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2018, 50 (02) : 437 - 451
  • [24] SiRNA targeting LATS2 promotes proliferation and invasion in breast cancer cells by regulating the Hippo pathway
    Hua, Kaiyao
    Zhao, Bingkun
    Jin, Jiali
    Xu, Hui
    Wu, Chenyang
    Li, Dengfeng
    Song, Hongming
    Song, Jialu
    Zhao, Junyong
    Fang, Lin
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9 (03): : 2765 - 2776
  • [25] WBP2 promotes gastric cancer cell migration via novel targeting of LATS2 kinase in the Hippo tumor suppressor pathway
    Hum, Melissa
    Tan, Hock Jin
    Yang, Yixuan
    Srivastava, Supriya
    Teh, Ming
    Lim, Yoon Pin
    FASEB JOURNAL, 2021, 35 (02)
  • [26] PLAGL2 promotes bladder cancer progression via RACGAP1/RhoA GTPase/YAP1 signaling
    Chen, Hualin
    Yang, Wenjie
    Li, Yingjie
    Ji, Zhigang
    CELL DEATH & DISEASE, 2023, 14 (07)
  • [27] RASAL2 promotes lung cancer metastasis through epithelial-mesenchymal transition
    Li, Ning
    Li, Suyun
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2014, 455 (3-4) : 358 - 362
  • [28] MicroRNA-103 promotes tumor growth and metastasis in colorectal cancer by directly targeting LATS2
    Zheng, Yong-Bin
    Xiao, Kuang
    Xiao, Gao-Chun
    Tong, Shi-Lun
    Ding, Yu
    Wang, Qiu-Shuang
    Li, Sheng-Bo
    Hao, Zhi-Nan
    ONCOLOGY LETTERS, 2016, 12 (03) : 2194 - 2200
  • [29] WNT5a Signaling through ROR2 Activates the Hippo Pathway to Suppress YAP1 Activity and Tumor Growth
    Wang, Keshan
    Ma, Fen
    Arai, Seiji
    Wang, Yun
    Varkaris, Andreas
    Poluben, Larysa
    Voznesensky, Olga
    Xie, Fang
    Zhang, Xiaoping
    Yuan, Xin
    Balk, Steven P.
    CANCER RESEARCH, 2023, 83 (07) : 1016 - 1030
  • [30] NOX4 promotes tumor progression through the MAPK-MEK1/2-ERK1/2 axis in colorectal cancer
    Xu, Yu-Jie
    Huo, Ya-Chang
    Zhao, Qi-Tai
    Liu, Jin-Yan
    Tian, Yi-Jun
    Yang, Lei-Lei
    Zhang, Yi
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 16 (04) : 1421 - 1436